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Background: Promyelocytic leukaemia zinc finger (PLZF) is a transcriptional repressor that was originally isolated
from a patient with promyelocytic leukaemia. PLZF also affects key elements for cell cycle progression, such as
cyclin A, and can affect the tumourigenicity of various cancers. Thus far, the behaviour of PLZF in thyroid carcinoma
remains unclear.
Methods: We analysed the expression profile of PLZF in different types of benign and malignant thyroid lesions as
well as in normal thyroid tissue. Specifically, we examined PLZF expression in normal thyroid (N; n = 4),
adenomatous lesion (AL; n = 5), follicular adenoma (FA; n = 2), papillary thyroid carcinoma (PTC; n = 20), and
anaplastic thyroid carcinoma (ATC; n = 3) samples. PLZF expression was estimated by western blotting and
immunohistochemical (IHC) staining.
Results: PLZF was expressed in all samples of thyroid lesions examined. In N, AL, and FA, PLZF was mainly localized
in the nucleus. In contrast, in PTC and ATC, PLZF was mainly expressed in the cytosol with high intensity. In more
detail, the cytoplasmic IHC scores in PTC with capsular invasion (CI) and lymph node (LN) metastasis were higher
than those in PTC without CI and LN metastasis.
Conclusions: PLZF shows different subcellular localizations among PTC, ATC, and other thyroid lesions.
Furthermore, high cytoplasmic expression of PLZF may be correlated with CI and LN metastasis in thyroid
carcinoma. The present report is the first to describe the implications of intracellular PLZF expression in thyroid
carcinomas.
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Thyroid carcinoma is the most frequently occurring en-
docrine cancer and one of the most rapidly increasing
cancers in humans [1,2]. The majority of patients with
thyroid carcinoma who undergo appropriate treatment
have an excellent outcome. However, in about 10% of
patients, the tumour loses its ability to take up radioio-
dine, or becomes poorly differentiated or redifferentiated,
leading to disease recurrence and death [3]. Therefore,
there is a compelling need for better understanding of* Correspondence: stani@med.tottori-u.ac.jp
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article, unless otherwise stated.thyroid tumourigenesis and improved treatment for these
cases.
Promyelocytic leukaemia zinc finger (PLZF), which
was first identified as a partner gene fused to retinoic
acid receptor alpha in the variant chromosomal trans-
location t(11;17)(q23;q21) in acute promyelocytic leukae-
mia, is a nuclear transcription factor belonging to the
BTB/POZ family [4-6]. Although PLZF is mainly linked
to haematological cancers, some recent studies have
reported a new role for PLZF in solid cancers, such
as melanomas and malignant mesothelioma [7,8]. Fur-
thermore, wild-type PLZF has been directly linked
to tumour suppression via its transcriptional repression
of the c-myc oncogene [9]. These findings indicate thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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through multiple mechanisms.
With regard to thyroid carcinoma, there have been no
reports describing the possible involvement of PLZF ex-
pression and its function. We presume that PLZF in the
thyroid may play a role in tumourigenesis. In the present
study, we analysed the expression and intracellular dis-




The study conformed to the principles outlined in the
Declaration of Helsinki, and was approved by the Ethics
Committee of the Faculty of Medicine, Tottori University.
All patients provided written informed consent. Thyroid
samples were obtained at surgery from patients as follows:
normal thyroid (N; n = 4); adenomatous lesion (AL;
n = 5); follicular adenoma (FA; n = 2); papillary thyroid
carcinoma (PTC; n = 20); anaplastic thyroid carcinoma
(ATC; n = 3). We performed immunohistochemical (IHC)
staining in all samples, whereas western blot analyses were
carried out using four samples of N (cases 1–4), five
samples of AL (cases 5–9), and 13 samples of PTC (cases
12–24). We performed IHC staining using four samples of
N, five samples of AL, two samples of FA, 20 samples of
PTC, and three samples of ATC. The characteristics of the
analysed samples are listed in Table 1.
Western blot analysis
Human thyroid tissues were homogenized in 300 μl of RIPA
buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, and
0.1% sodium dodecyl sulphate in PBS with a protease inhibi-
tor cocktail (Roche Molecular Biochemicals, Indianapolis,
IN)) and centrifuged at 15000 rpm for 20 min at 4°C. The
supernatants were used as the total cell lysates. A aliquot
(10 μg protein) of each lysate was subjected to 10% SDS-
PAGE, and the separated proteins were electrophoretically
transferred to nitrocellulose membranes. The membranes
were blocked with Tris-buffered saline containing 0.05%Table 1 Summary of the thyroid neoplasm histotypes
evaluated and the patient sex and age distributions
Histotypes n Age Sex (M/F)
Normal thyroid 4 67 ± 15 2/2
Adenomatous lesion 5 43 ± 11 0/5
Follicular adenoma 2 32 ± 9 0/2
Papillary carcinoma 20 57 ± 16 4/16
CI(-), LN meta(-) 5 51 ± 23 2/3
CI(+), LN meta(-) 8 64 ± 13 0/8
CI(+), LN meta(+) 7 51 ± 13 2/5
Anaplastic carcinoma 3 68 ± 9 2/1
CI; capsular invasion, LN meta; lymphnode metastasis.Tween-20 and 5% non-fat dried milk, washed, and incu-
bated with polyclonal primary antibodies against PLZF
(sc-22839; Santa Cruz Biotechnology Inc., Santa Cruz,
CA; 1:200 dilution) and β-actin (sc-1616; Santa Cruz
Biotechnology Inc.; 1:500 dilution). The membranes
were then exposed to an anti-rabbit secondary antibody
(NA934; Amersham Pharmacia Biotech, Little Chalfont,
UK; 1:5000 dilution). After incubation with the secondary
antibody, detection of the bound antibodies was per-
formed using enhanced chemiluminescence.IHC evaluation of PLZF expression
PLZF expression was analysed by IHC staining of thyroid
samples. Paraffin-embedded tissue sections (4-μm thick-
ness) were deparaffinized in xylene and rehydrated through
a graded alcohol series to deionized water. After micro-
wave antigen retrieval, the endogenous peroxidase activity
was blocked with H2O2. The sections were then sequen-
tially incubated with the anti-PLZF primary antibody (1:50
dilution) for 12 h at 4°C, and a peroxidase-labelled anti-
rabbit secondary antibody (414141 F; Nichirei, Tokyo,
Japan) for 30 min at room temperature. After colour deve-
lopment with 3,3′-diaminobenzidine and counterstaining
with haematoxylin, the sections were scanned at various
magnifications (×100 to × 400) using light microscopy.
The proportions of positively stained cells and the
intensity scores were evaluated by two experienced pro-
fessionals. The Allred scoring system [10] was used for
PLZF staining interpretation. The proportion of posi-
tively stained cells was rated as follows: 0%, no positive
staining; 1, between 0% and 1% positive staining; 2, bet-
ween 1% and 10% positive staining; 3, between 10% and
33% positive staining; 4, between 33% and 66% positive
staining; 5, between 66% and 100% positive staining. In
addition to the proportion score, an intensity score was
made on the basis of the average intensity of staining as
follows: 0, negative; 1, weak; 2, intermediate; 3, strong.
The intensity score and proportion score were added to
obtain the total score, termed the IHC score, which is
referred to as the Allred score [10] and is either 0 or bet-
ween 2 and 8.Statistical analysis
The western blotting values by densitometric analysis
and IHC scores for the individual samples were com-
pared by the Tukey’ HSD test. The IHC scores were
compared between the nucleus and cytoplasm, and bet-
ween positivity or negativity for capsular invasion (CI)
and lymph node (LN) metastasis in PTC using the
Mann–Whitney U test. Values of p < 0.05 were consi-
dered to indicate statistical significance. All statistical
analyses were performed using SPSS 14.0 for Windows
(SPSS Corp., Tokyo, Japan).
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Expression of PLZF in human thyroid samples
We estimated PLZF expression by western blot analyses.
All samples were confirmed to express PLZF (Figure 1A
and B). All samples of PTC showed high expression of
PLZF (Figure 1B). Conversely, the PLZF expression
levels were relatively low in N and AL compared with
PTC (Figure 1A). To compare the PLZF expression
levels between different membranes, we used the PLZF
expression ratios, representing the densitometrically
analysed data for each membrane divided by the mean
value for N, which was used as an internal control
(Figure 1C). The PLZF/actin expression ratio was signifi-
cantly higher in PTC than in both N and AL (p < 0.05).
Localization of PLZF in different types of benign and
malignant thyroid lesions
We estimated the intracellular distribution of PLZF by
IHC staining. In N (Figure 2A), PLZF was mainly loca-
lized in the nucleus. The strength of its expression
ranged from intermediate to strong. However, the ex-
pression of PLZF in the cytosol was faint or absent. The
IHC scores were 4–7 in the nucleus and 0 or 2 in the
cytosol. In AL (Figure 2B), PLZF was mainly localized in
the nucleus, and its strength was intermediate or strong.
In the cytosol, the PLZF expression was weak, but
slightly stronger than in N. The IHC scores were 5–8 in




Case 1 2 3 4 5 6 7 8 9 12
C
Figure 1 Western blot analyses of PLZF in normal thyroid, adenomato
immunoblotting, an aliquot (10 μg protein) of each lysate was loaded. To c
used the PLZF/β-actin expression ratios, representing the densitometrically
normal thyroid tissues, which was used as an internal control (C). *p < 0.05
adenomatous lesion and papillary thyroid carcinoma.PLZF was mainly localized in the nucleus. In the cytosol,
the PLZF expression was stronger than in N. The IHC
scores were 7 or 8 in the nucleus and 4 in the cytosol.
In almost all samples of PTC, the PLZF expression in
the nucleus was absent or very weak. In general, the
PLZF expression was strong in the cytosol. However, the
proportion of positive cells and the intensity of staining
varied according to each case. As shown in Figure 2D,
the intensity of PLZF staining was very weak or absent
and the proportion of positive cells was low. Conversely,
as shown in Figure 2E, the intensity of PLZF staining
was strong and the proportion was high, despite the
same histotype (PTC). In all samples of ATC (Figure 2F),
PLZF was localized in the cytosol and the intensity of
staining was high, resembling the findings shown in
Figure 2E.
We clarified the staining patterns of PLZF between be-
nign and malignant thyroid lesions by grading using the
IHC scores. In benign lesions, such as N, AL, and FA,
PLZF was localized in the nucleus (Figure 3A). In con-
trast, in malignant lesions, such as PTC and ATC, PLZF
was localized in the cytosol (Figure 3B). There was a
significant difference between benign and malignant
thyroid lesions.
Subsequently, we examined PTC in more detail be-
cause there were different proportions and intensities of
IHC staining in the cytosol. We classified PTC according
to CI and LN metastasis. As shown in Figure 4A, thePapillary carcinoma
13 14 15 16 17 18 19 20 21 22 23 24
us lesion (A), and papillary thyroid carcinoma (B) samples. For
ompare the PLZF expression levels among different membranes, we
analysed data for each membrane divided by the mean value for




Figure 2 PLZF expression in a normal thyroid, an adenomatous lesion, a follicular adenoma, two papillary thyroid carcinomas with
different degrees of capsular invasion and lymph node metastasis, and an anaplastic thyroid carcinoma representative of our study
population. All images are × 400 magnification. IHC: immunohistochemical; N/C: nucleus/cytoplasm. (A) Normal thyroid showing nuclear staining
(IHC score: N/C = 7/2). (B) Adenomatous lesion showing strong nuclear staining with intermediate cytoplasmic staining (IHC score: N/C = 7/3).
(C) Follicular adenoma showing strong nuclear staining with intermediate cytoplasmic staining (IHC score: N/C = 7/4). (D) Papillary thyroid
carcinoma without capsular invasion and lymph node metastasis showing faint cytoplasmic staining (IHC score: N/C = 0/3). (E) Papillary thyroid
carcinoma with both capsular invasion and lymph node metastasis showing strong cytoplasmic staining (IHC score: N/C = 0/8). (F) Anaplastic
thyroid carcinoma showing strong cytoplasmic staining (IHC score: N/C = 0/8).
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metastasis(-) to CI(+)LN metastasis(-), CI(+)LN metasta-
sis(+), and ATC, albeit without statistical significance.
The IHC scores in samples with CI were higher than
those in samples without CI (Figure 4B), although the
difference was not significant. With respect to LN me-
tastasis, the PLZF expression levels in samples with LN
metastasis were significantly higher than those in sam-
ples without LN metastasis (Figure 4C).
Discussion
PLZF expression has been detected in most human tis-
sues [11]. However, its expression in the thyroid has not
been reported. By western blot analyses, we were able toconfirm PLZF expression in N, AL, and PTC, and
showed that PLZF was expressed at quite high levels in
PTC compared with N and AL. PLZF is known to be a
transcriptional repressor, and is associated with suppres-
sion of cellular proliferation. In a variety of cell models,
sustained PLZF expression was associated with cell cycle
arrest in G1 and eventual apoptosis [12-14]. Therefore,
we presumed that the PLZF expression in benign thyroid
samples would be higher than that in malignant samples.
However, our results indicated alternative expression
levels. In a previous report on myeloid cell lines, cyto-
kines were shown to mediate inactivation of PLZF by
triggering its export from the nucleus in an ERK-
dependent manner, leading to interference with PLZF-
Figure 3 Comparison of PLZF expression between the nucleus and cytosol of benign and malignant tumours. (A, B) Differences in PLZF
expression between the nucleus and cytosol of benign tissues (A) and malignant tissues (B). *p < 0.05, nucleus vs. cytosol; **p < 0.05, benign
tissues vs. malignant tissues. Open circle: normal thyroid; filled circle: adenomatous lesion; open square: follicular adenoma; open triangle:
papillary thyroid carcinoma; filled triangle: anaplastic thyroid carcinoma.
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In this manner, PLZF was required to be localized in the
nucleus to perform its functional roles. Therefore, the
intracellular localization of PLZF would be as important
as the amount of its expression.
To investigate the localization of PLZF, we performed
IHC staining in different types of benign and malignant
thyroid lesions as well as in normal thyroid tissue. Our
findings revealed a significant difference in PLZF loca-
lization between benign and malignant thyroid lesions.
As one of the mechanisms for PLZF intracellulartranslocation, Nanba et al. [16] reported that heparin-
binding EGF-like growth factor (HB-EGF) generated by
ectodomain shedding of proHB-EGF causes nuclear ex-
port of PLZF, increases the expression of cyclin A, and
promotes S-phase entry. Furthermore, an interaction bet-
ween the HB-EGF carboxy-terminal region (HB-EGF-C)
and PLZF occurs in a mouse skin model of keratinocyte
hyperplasia. Ota et al. [17] reported that in clinical IHC
study, increased expression of HB-EGF was observed in
thyroid carcinoma samples more than benign thyroid









































Figure 4 Comparison of PLZF expression in the cytoplasm among papillary thyroid carcinomas and anaplastic thyroid carcinomas.
(A) The papillary thyroid carcinoma samples were classified according to capsular invasion and lymph node metastasis. (B, C) Differences in cytosolic
PLZF expression between capsular invasion-positive and capsular invasion-negative tumours (B) and between lymph node metastasis-positive and
lymph node metastasis-negative tumours (C). Open circle: papillary thyroid carcinoma without capsular invasion and lymph node metastasis; open
triangle: papillary thyroid carcinoma with capsular invasion; white diamond: papillary thyroid carcinoma with lymph node metastasis; filled circle:
anaplastic thyroid carcinoma.
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able to presume that the similar mechanism involving
HB-EGF-C may lead to the translocation of PLZF in PTC
and APC.
When we observed the IHC scores for PTC in more
detail, the cytoplasmic IHC scores in PTC with CI and
LN metastasis were higher than those in PTC without
CI and LN metastasis. These findings indicate that the
strength of PLZF expression in the cytosol reflects theprogression of malignancy, such as CI and LN metasta-
sis. A previous report suggested that down-regulation of
microRNA-126 and -126* may be a key event in mela-
noma progression [18]. These microRNAs play a tumour
suppressor role in human melanoma through down-
modulation of two metalloproteinases, ADAM9 and
MMP7, resulting in decreased HB-EGF activation [18].
This mechanism was thought to eventually bring about
export of PLZF from the nucleus to the cytosol. If this
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correlated with melanoma progression. Although we
were unable to clarify whether the same mechanism acts
in the thyroid, our findings suggest a hypothesis that the
amount of PLZF in the cytoplasm may be one of the
possible causes of the progression of thyroid carcinoma.
The interaction between HB-EGF-C and PLZF is consi-
dered to be a novel therapeutic target. In a previous study,
Telmisartan was found to block the binding of HB-EGF-C
to PLZF, and inhibit the cell proliferation of human colon
cancer cell lines [19]. Replacement of microRNA-126
and -126* might be considered a promising therapeutic ap-
proach against malignant melanoma [18]. In this study, we
could not clarify the reason why PLZF is translocated to
the cytoplasm and highly expressed in the cytosol during
PTC progression. Therefore, further studies are necessary
to reveal the underlying mechanism. If a similar me-
chanism to colon cancer and malignant melanoma exists
for thyroid carcinoma, PLZF localization may be a novel
therapeutic target to suppress the progression of thyroid
carcinoma.Conclusion
In the present study, we have demonstrated four impor-
tant findings about PLZF in thyroid samples. First, we
confirmed that PLZF is expressed in the thyroid. Second,
the levels of PLZF expression were greater in PTC than in
N and AL. Third, the intracellular localization of PLZF in
PTC and ATC showed a different pattern compared with
benign thyroid lesions. Finally, as thyroid carcinoma pro-
gressed through CI, LN metastasis, and ATC, the PLZF
expression became higher. To our knowledge, this is the
first report to describe the expression and localization of
PLZF in the thyroid. The present results suggested that
the cytosolic localization and intensity of PLZF expression
may be correlated with thyroid tumourigenicity and degree
of malignancy.Abbreviations
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